Inactivated whole-cell bacterial vaccines: Current status and novel strategies

Vaccine

Volumn 16, Issue 16, 1998, Pages 1563-1574

  Pace, John L ^a   Rossi, Humberto A ^b   Esposito, Vito M ^a   Frey, Steve M ^c   Tucker, Kenneth D ^a   Walker, Richard I ^a  

^a Antex Biologics   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c ICOS Pharmaceuticals   (United States)

Author keywords

Bacteria; Inactivated; Vaccines; Whole cell

Indexed keywords

BACTERIAL VACCINE; CAMPYLOBACTER JEJUNI VACCINE; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; ESCHERICHIA COLI VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; INACTIVATED VACCINE; LISTERIA MONOCYTOGENES VACCINE; PERTUSSIS VACCINE; PSEUDOMONAS VACCINE; SALMONELLA TYPHIMURIUM VACCINE; SALMONELLOSIS VACCINE; SHIGELLA VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BORDETELLA PERTUSSIS; CAMPYLOBACTER JEJUNI; CHOLERA; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DYSENTERY; ESCHERICHIA COLI; GASTROENTERITIS; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; INTRADERMAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; SHIGELLA FLEXNERI; STREPTOCOCCUS; STREPTOCOCCUS INFECTION; VIBRIO CHOLERAE;

ANIMALS; BACTERIAL VACCINES; HUMANS; VACCINES, INACTIVATED;

EID: 18544405340     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00046-2     Document Type: Article

References (169)

1. 1 Cohen, M.L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992, 257, 1050.
2. 2 Neu, H.C. The crisis in antibiotic resistance. Science 1992, 257, 1064.
3. 3 Wilson, M.E. Travel and the emergence of infectious diseases. Emerg. Infect. Dis. 1995, 1, 39.
4. 4 Hughes, J.M. and Tenover, F.C. Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations. Clin. Infect. Dis. 1997, 24, S131.
5. 5 Thomson, D., Thomson, R. and Morrison, J.T. Oral Vaccines, and Immunization by other Unusual Routes. Williams and Wilkins, Baltimore, MD, 1948, p. 357.
6. 6 Mochmann, H. and Ocklitz, H.W. Oral immunization against enteric infectins using inactivated bacteria. A review. Acta Microbiol. Acad. Sci. Hung. 1974, 21, 3.
7. 7 Holmgren, J., Svennerholm, A.M., Clemens, J., Sack, D., Black, R. and Levine, M. An oral B subunit-whole cell vaccine against cholera: from concept to successful field trial. Adv. Exp. Med. Biol. 1987, 216B, 1649.
8. 8 Hone, D. and Hackett, J. Vaccination against enteric bacterial diseases. Rev. Infect. Dis. 1989, 11, 853.
9. 9 Holmgren, J. and Svennerholm, A.M. New vaccines against bacterial enteric infections. Scand. J. Infect. Dis. 1990, 70, S149.
10. 10 Holmgren, J. and Svennerholm, A.M. Development of oral vaccines against cholera and enterotoxinogenic Escherichia coli diarrhea. Scand. J. Infect. Dis. 1990, 76, 47.
11. 11 Holmgren, J., Czerkinsky, C., Lycke, N. and Svennerholm, A.M. Mucosal immunity: implications for vaccine development, Immunobiology 1992, 184, 157.
12. 12 Dougan, G. The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development. Microbiology 1994, 140, 215.
13. 13 Ellis, R.W. New Technologies for making vaccines. In: Vaccines (Eds Plotkin, S.A. and Mortimer, E.A. Jr), 2nd edn. W.B. Saunders, Philadelphia, PA, 1994, p. 867.
14. 14 Peterson, J.W. Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine. Infect. Immun. 1979, 26, 528.
15. 15 Angerman, C.R. and Eisenstein, T.K. Corelation of the duration and magnitude of protection against Salmonella infection afforded by various vaccines with antibody titres. Infect. Immun. 1980, 27, 435.
16. 16 Ashworth, L.A.E., Robinson, A., Irons, L.I. and Morgan, C.P. Antigens in whooping cough vaccine and antibody levels induced by vaccination of children. Lancet 1983, 2, 878.
17. 17 Keren, D.F., Scott, P.J., McDonald, R.A. and Wiatrak, M. Effect of parenteral immunization on the local immunoglobulin A response of the intestine to Shigella flexneri antigens. Infect. Immun. 1983, 42, 202.
18. 18 Jertborn, M., Svennerholm, A.M. and Holmgren, J. Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in swedes after oral immunization with B subunit-whole cell cholera vaccine. Int. Arch. Allergy Appl. Immunol. 1984, 75, 38.
19. 19 Trollfors, B. Bordetella pertussis whole cell vaccines-efficacy and toxicity. Acta Paediatr. Scand. 1984, 73, 417.
20. 20 Baumann, E., Binder, B.R., Falk, W., Huber, E.G., Kurz, R. and Rosanelli, K. Development and clinical use of an oral heat-inactivated whole cell pertussis vaccine. Dev. biol. Stand. 1985, 61, 511.
21. 21 Clancy, R.L., Cripps, A., Maureen-Allen, K., Yeung, S. and Engel, M. Oral immunization with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet 1985, 2, 1395.
22. 22 Lycke, N., Lindholm, L. and Holmgren, J. Cholera antibody production in vitro by peripheral blood lymphocytes following oral immunization of humans and mice. Clin. Exp. Immunol. 1985, 62, 39.
23. 23 Dolby, J.M. and Newell, D.G. The protection of infant mice from colonization with Campylobacter jejuni by vaccination of the dams. J. Hyg. 1986, 96, 143.
24. 24 Black, R.E., Levine, M.M., Clements, M.L., Young, C.R., Svennerholm, A.M. and Holmgren, J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun. 1987, 55, 1116.
25. 25 Holmgren, J., Svennerholm, A.M., Clemens, J., Sack, D., Black, R. and Levine, M. An oral B subunit-whole cell vaccine against cholera: from concept to successful field trial. Adv. Exp. Med. Biol. 1987, 216B, 1649.
26. 26 Bronze, M.S., McKinsey, D.S., Beachey, E.H. and Dale, J.B. Protective immunity evoked by locally administered group A streptococcal vaccines in mice. J. Immunol. 1988, 141, 2767.
27. 27 Clemens, J.D., Harris, J.R., Sack, D.A., Chakraborty, J., Ahmed, F., Stanton, B.F., Khan, M.U., Kay, B.A., Huda, N. and Khan, M.R. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J. Infect. Dis. 1988, 158, 60.
28. 28 Evans, D.J. Jr., Evans, D.G., Opekun, A.R. and Graham, D.Y. Immuno-protective oral whole cell vaccine for enterotoxigenic Escherichia coli diarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2. FEMS Microbiol. Immunol. 1988, 1, 9.
29. 29 Ribble, C.S., Jim, G.K. and Janzen, E.D. Efficacy of immunization of feedlot calves with commercial Haemophilus somnus bacterin. Can. J. Vet. Res. 1988, 52, 191.
30. 30 Abimiku, A.G., Dolby, J.M. and Borriello, S.P. Comparison of different vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse. Epidemiol. Infect. 1989, 102, 271
31. 31 Clemens, J.D., Harris, J.R., Kay, B.A., Chakraborty, J., Sack, D.A., Ansaruz-zaman, M., Rahman, R., Stanton, B.F., Khan, M.U. and Khan, M.R. Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. II. Field evaluation of cross-protection against other members of the Vibrionaceae family. Vaccine 1989, 7, 117.
32. 32 Freihorst, J., Merrick, J.M. and Ogra, P.L. Effect of oral immunization with Pseudomonas aeruginosa on the development of specific antibacterial immunity in the lungs. Infect. Immun. 1989, 57, 235.
33. 33 George, A., Shroff, K.E., Rath, S., Ghosh, S.N., Sengupta, S.R. and Kamat, R.S. Route-related variation in the immunogenicity of killed Salmonella enteritidis vaccine: role of antigen presenting cells. Microbiol. Immunol. 1989, 33, 479.
34. 34 Mikula, I., Rosocha, J. and Pilipcinec, E. Immunization of calves with live and inactivated whole-cell vaccines against Salmonella typhimurium infection. Acta Vet. Hung. 1989, 37, 219.
35. 35 Muotiala, A., Hovi, M. and Makela, P.H. Protective immunity in mouse salmonellosis: comparison of smooth and rough live and killed vaccines. Microb. Pathog. 1989, 6, 51.
36. 36 Smart, N.L. and Miniats, O.P. Preliminary assessment of a Haemophilus parasuis bacterin for use in specific pathogen free swine. Can. J. Vet. Res. 1989, 53, 390.
37. 37 Clancy, R.L., Cripps, A.W. and Gebski, V. Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae. Med. J. Aust. 1990, 152, 413.
38. 38 Hougen, H.P., Jensen, E.T. and Klausen, B. Experimental Salmonella typhimurium infections in rats. II. Active and passive immunization as protection against a lethal bacterial dose. APMIS 1990, 98, 30.
39. 39 Lehmann, D., Coakley, K.J., Coakley, C.A., Spooner, V., Montgomery, J.M., Michael, A., Riley, I.D., Smith, T., Clancy, R.L. and Cripps, A.W. Reduction in the incidence of acute bronchitis by an oral vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. Am. Rev. Respir. Dis. 1991, 144, 324.
40. 40 Pelitola, H., Siitonen, A., Kyronseppa, H., Simula, I., Mattila, L., Oksanen, P., Kataja, M.J. and Cadoz, M. Prevention of travellers' diarrhea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991, 338, 1285.
41. 41 Sack, D.A., Clemens, J.D., Huda, S., Harris, J.R., Khan, M.R., Chakraborty, J., Yunus, M., Gomes, J., Siddique, O., Ahmed, F., Kay, B.A., van Loon, F.P.L., Rao, M.R., Svennerholm, A.M. and Holmgren, J. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J. Infect. Dis. 1991, 164, 407.
42. 42 Uchiya, K., Nikai, T. and Sugihara, H. Difference in the protection against infection with different challenge strains of Salmonella enteritidis by killed vaccine. Kansenshogaku Zasshi. 1991, 65, 1411.
43. 43 Clemens, J.D., Sack, D.A., Rao, M.R., Chakraborty, J., Khan, M.R., Kay, B., Ahmed, F., Banik, A.K., van Loon, F.P. and Yunus, M. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area. J. Infect. Dis. 1992, 166, 1029.
44. 44 Gast, R.K., Stone, H.D., Holt, P.S. and Beard, C.W. Evaluation of the efficacy of an oil-emulsion bacterin for protecting chickens against Salmonella enteritidis. Avian Dis. 1992, 36, 992.
45. 45 Walker, P.D. Bacterials vaccines: old and new, veterinary and medical. Vaccine 1992, 10, 977.
46. 46 Wenneras, C., Svennerholm, A.M., Ahren, C. and Czerkinsky, C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect. Immun. 1992, 60, 2605.
47. 47 Rollwagen, F.M., Pacheco, N.D., Clements, J.D., Pavlovskis, O.R., Rollins, D.M. and Walker, R.I. Killed Campylobacter elicits immune responses and protection when administered with an oral adjuvant. Vaccine 1993, 11, 1316.
48. 48 Sanchez, J.L., Trofa, A.F., Taylor, D.N., Kuschner, R.A., DeFraites, R.F., Craig, S.C., Rao, M.R., Clemens, J.D., Svennerholm, A.M., Sadolf, J.C. and Holmgren, J. Safety and immunogenicity of the oral whole cell/ recombinant B subunit cholera vaccine in North American volunteers. J. Infect. Dis. 1993, 167, 1446.
49. 49 Cripps, A.W., Dunkley, M.L. and Clancy, R.L. Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect. Immun. 1994, 62, 1427.
50. 50 Baqar, S., Bourgeois, A.L., Schultheiss, P.J., Walker, R.I., Rollins, D.M., Haberberger, R.L. and Pavlovskis, O.R. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with mucosal adjuvant in non-human primates. Vaccine. 1994, 13, 22.
51. 51 Baqar, S., Applebee, L.A. and Bourgeois, A.L. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infect. Immun. 1995, 63, 3731.
52. 52 Begue, R.E., Castellares, G., Ruiz, R., Hayashi, K.E., Sanchez, J.L., Gatuzzo, E., Oberst, R.B., Taylor, D.N. and Svennerholm, A.M. Community based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBDS) oral cholera vaccine in Peru. Vaccine 1995, 13, 691.
53. 53 Concha, A., Giraldo, A., Castaneda, E., Martinez, M., De La Hong, F., Rivas, F., Depetris, A., Svennerholm, A.M. and Sack, D.A. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla. Colombia. Bull. PAHO 1995, 29, 312.
54. 54 Cripps, A.W., Dunkley, M.L., Clancy, R.L. and Kyd, J. Pulmonary immunity to Pseudomonas aeruginosa. Immunol. Cell. Biol. 1995, 73, 418.
55. 55 Mukkur, T.K., Walker, K.H., Baker, P. and Jones, D. Systemic and mucosal intestinal antibody response of sheep immunized with aromatic-dependent live or killed Salmonella typhimurium. Comp. Immunol. Microbiol. Infect. Dis. 1995, 18, 27.
56. 56 Nayir, A., Emre, S., Sirin, A., Bulut, A., Alpay, H. and Tanman, F. The effects of vaccination with inactivated uropathogenic bacteria in recurrent urinary tract infections of children. Vaccine 1995, 13, 987.
57. 57 Redhead, R. Pertussis vaccines-old and new. In: Molecular and Clinical Aspects of Bacterial Vaccine Development (Eds Ala' Aldeen, D.A.A. and Hormaeche, C.E.). Wiley, New York, 1995, p. 260.
58. 58 Roberts, J.A., Kaack, M.B., Baskin, G. and Svenson, B. Vaccination with a formalin-killed P-fimbriated E. coli whole-cell vaccine prevents renal scarring from pyelonephritis in the non-human primate. Vaccine 1995, 13, 11.
59. 59 Wenneras, C., Czerkinsky, C. and Svennerholm, A.M. Vaccine-specific T cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. In: Advances in Mucosal Immunology (Eds Mestecky, J. et al.). Plenum Press, New York, 1995, p. 164.
60. 60 Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A.E., Anemona, A., Ciofi Degli Atti, M.L., Giammanco, A., Panei, P., Blockwelder, W.G., Klein, D.L., Wassilak, S.G.F. and The Progetto Pertosse Working Group, A controlled trial of two accellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 1996, 334, 341.
61. 61 Gustafsson, L., Hollander, H.O., Olin, P., Reizerstein, E. and Slorsaeter, J. A controlled trial of a two component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 1996, 334, 349.
62. 62 van Loon, F.P.L., Clemens, J.D., Chakraborty, J., Rao, M.R., Kay, B.A., Sack, D.A., Yumus, M., Ali, M., Svennerholm, A.M. and Holmgren, J. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 1996, 14, 162.
63. 63 Evans, D.G., Graham, D.Y., Evans, D.J. Jr. and Opekun, A. Administration of purified colonization factor antigens (CFA/I, CFA/II) of enterotoxigenic Escherichia coli to volunteers. Response to challenge with virulent enterotoxigenic Escherichia coli. Gastroenterol. 1984, 87, 934.
64. 64 Svennerholm, A.M., Jertborn, M., Gothefors, L., Karim, A.M., Sack, D.A. and Holmgren, J. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J. Infect. Dis. 1984, 149, 884.
65. 65 Lycke, N., Hellstrom, U. and Holmgren, J. Circulating cholera antitoxin memory cells in the blood one year after oral cholera vaccination in humans. Scand. J. Immunol. 1987, 26, 207.
66. 66 Evans, D.G., Graham, D.Y., Evans, D.J. Jr. and Opekun, A. Administration of purified colonization factor antigens (CFA/I, CFA/II) of enterotoxigenic Escherichia coli to volunteers. Response to challenge with virulent enterotoxigenic Escherichia coli. Gastroenterology 1984, 87, 934.
67. 67 Jertborn, M., Svennerholm, A.M. and Holmgren, J. IgG and IgA subclass distribution of antitoxin antibody responses after oral cholera vaccination or cholera disease. Int. Arch. Allergy Appl. Immunol. 1988, 85, 358.
68. 68 Thomas, M.G., Ashworth, L.A., Miller, E. and Lambert, H.P. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. J. Infect. Dis. 1989, 160, 838.
69. 69 Dragunsky, E.M., Rivera, E., Aaronson, W., Dolgaya, T.M., Hochstein, H.D., Habig, W.H. and Levenbook, I.S. Experimental evaluation of antitoxic protective effect of new cholera vaccines in mice. Vaccine 1992, 10, 735.
70. 70 Osek, J., Svennerholm, A.M. and Holmgren, J. Protection against Vibrio cholerae El Tor infection by specific antibodies against mannose-binding hemagglutinin pili. Infect. Immun. 1992, 60, 4961.
71. 71 Sengupta, D.K., Sengupta, T.K. and Ghose, A.C. Major outer membrane proteins of Vibrio cholerae and their role in induction of protective immunity through inhibition of intestinal colonization. Infect. Immun. 1992, 60, 4848.
72. 72 Evans, D.G., Evans, D.J. Jr. and DuPont, H.L. Virulence factors of enterotoxigenic Escherichia coli. J. Infect. Dis. 1977, 136, S118.
73. 73 Lodinova-Zadnikova, R., Korych, B. and Gajdlostikova, K. Local and systemic antibody response in infants after oral administration of inactivated entero-pathogenic E. coli serotype O111 and O55. Folia Microbiol. 1990, 35, 155.
74. 74 Finch, J.M., Hill, A.W., Field, T.R. and Leigh, J.A. Local vaccination with killed Streptococcus uberis protects the bovine mammary gland against experimental intramammary challenge with the homologous strain. Infect. Immun. 1994, 62, 3599.
75. 75 Gilmour, N.J.L., Donachie, W., Sutherland, A.D., Gilmour, J.S., Jones, G.E. and Quirle, M. Vaccine containing iron-regulated proteins of Pasteurella haemolytica A2 enhances protection against experimental pasteurellosis in lambs. Vaccine 1991, 9, 137.
76. 76 Szalay, G., Ladel, C.H. and Kaufmann, S.H.E. Stimulation of protective CD8+T lymphocytes by vaccination with nonliving bacteria. Proc. Natl Acad. Sci. U S A 1995, 92, 12389.
77. 77 Thatte, J., Rath, S. and Bal, V. Analysis of immunization route-related variation in the immune response to heat-killed Salmonella typhimurium in mice. Infect. Immun. 1995, 63, 99.
78. 78 Mekalanos, J.J. Environmental signals controlling expression of virulence determinants in bacteria. J. Bacteriol. 1992, 174, 1.
79. 79 Konkel, M.E., Mead, D.J. and Cieplak, W. Jr. Kinetic and antigenic characterization of altered protein synthesis by Campylobacter jejuni during cultivation with human epithelial cells. J. Infect. Dis. 1993, 168, 948.
80. 80 Forsberg, A. and Rosqvist, R. In vivo expression of virulence genes of Y. pseudotuberculosis. Infect. Agents Dis. 1994, 2, 275.
81. 81 Payne, S.M. and Finkelstein, R.A. Detection and differentiation of iron-responsive avirulent mutants on congo red agar. Infect. Immun. 1977, 18, 94.
82. 82 Brubaker, R.R. The Vwa+ virulence factor of yersiniae: the molecular basis of the attendant nutritional requirement for Ca++. Rev. Infect. Dis. 1983, 5, S748.
83. 83 Lawlor, K.M., Daskaleros, P.A., Robinson, R.E. and Payne, S.M. Virulence of iron transport mutants of Shigella flexneri and utilization of host iron compounds. Infect. Immun. 1987, 55, 594.
84. 84 Lorian, V. In vitro stimulation of in vivo conditions: physical state of the culture medium. J. Clin. Microbiol. 1989, 27, 2403.
85. 85 Maurelli, A.T. Temperature regulation of virulence genes in pathogenic bacteria: a general strategy for human pathogens?. Microb. Pathogen. 1989, 7, 1.
86. 86 Miller, J.F., Mekalanos, J.J. and Falkow, S. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science. 1989, 243, 916.
87. 87 Galán, J.E. and Curtiss, R. III Expression of Salmonella typhimurium genes required for invasion is regulated by changes in DNA supercoiling. Infect. Immun. 1990, 58, 1879.
88. 2+ response virulence genes. J. Bacteriol. 1991, 173, 2649.
89. 89 Tobe, T., Nagai, S., Okada, N., Adler, B., Yoshikawa, M. and Sasakawa, C. Temperature-regulated expression of invasion genes in Shigella flexneri is controlled through the transcriptional activation of the virB gene on the large plasmid. Molec. Microbiol. 1991, 5, 887.
90. 90 Andrews, G.P. and Maurelli, A.T. mxiA of Shigella flexneri 2a, which facilitates export of invasion plasmid antigens, encodes a homolog of the low-calcium-response protein LcrD of Yersinia pestis. Infect. Immun. 1992, 60, 3287.
91. 91 Francis, C.L., Starnbach, M.N. and Falkow, S. Morphological and cytoskeletal changes in epithelial cells occur immediately upon interaction with Salmonella typhimurium grown under low-oxygen conditions. Molec. Microbiol. 1992, 6, 3077.
92. 92 Maurelli, A.T., Hromockyj, A.E. and Bernardini, M.L. Environmental regulation of Shigella virulence. Curr. Top. Microbiol. Immunol. 1992, 180, 95.
93. 93 Gross, R. Signal transduction and virulence regulation in human and animal pathogens. FEMS Microbiol. Rev. 1993, 104, 301.
94. 94 Ginocchio, C.C., Olmstead, S.B., Wells, C.L. and Galán, J.E. Contact with epithelial cells induces the formation of surface appendages on Salmonella typhimurium. Cell 1994, 76, 717.
95. 2+ in the Yersinia low-calcium response. Molec. Microbiol. 1993, 8, 1005.
96. 96 Fowler, J.M. and Brubaker, R.R. Physiological basis of the low calcium response in Yersinia pestis. Infect. Immun. 1994, 62, 5234.
97. 97 Gardel, C.L. and Mekalanos, J.J. Regulation of cholera toxin by temperature, pH, and osmolarity. Meth. Enzymol. 1994, 235, 517.
98. 98 Pace, J., Rossi, H.A. and Chai, T. The effect of bile on Vibrio parahaemolyticus. In: FASEB Summer Conf. Principles of Viral, Bacterial, and Protozoan Pathogenesis, 1994.
99. 99 Pepe, J.C., Badger, J.L. and Miller, V.L. Growth phase and low pH affect the thermal regulation of the Yersinia enterocolitica inv gene. Molec. Microbiol. 1994, 11, 123.
100. 100 Sirard, J.C., Mock, M. and Fouet, A. The three Bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature. J. Bacteriol. 1994, 176, 5188.
101. 101 Straley, S.C. and Perry, R.D. Environmental modulation of gene expression and pathogenesis in Yersinia. Trends Microbiol. 1995, 3, 310.
102. 102 Mills, M. and Payne, S.M. Genetics and regulation of heme iron transport in Shigella dysenteriae and detection of an analogous system in Escherichia coli O157:H7. J. Bacteriol. 1995, 177, 3004.
103. 103 Pope, L.M., Reed, K.E. and Payne, S.M. Increased protein secretion and adherence to HeLa cells by Shigella spp. following growth in the presence of bile salts. Infect. Immun. 1995, 63, 3642.
104. 104 Mel, S.F. and Mekalanos, J.J. Modulation of horizontal gene transfer in pathogenic bacteria by in vivo signals. Cell 1996, 87, 795.
105. 105 Pace, J., Chai, T., Rossi, H.A. and Ji ang, X. The effect of bile on Vibrio parahaemolyticus. Appl. Environ. Microbiol. 1997, 63, 2372.
106. 106 Grant, C.C.R., Konkel, M.E., Cieplak, W. Jr. and Tompkins, L.S. Role of flagella in adherence, internalization, and translocation of Campylobacter jejuni in nonpolarized and polarized epithelial cell cultures. Infect. Immun. 1993, 61, 1764.
107. 107 Maurelli, A.T., Blackmon, B. and Curtiss, R. III Temperature dependent expression of virulence genes in Shigella species. Infect. Immun. 1984, 43, 195.
108. 108 Maurelli, A.T. and Curtiss, R. III Bacteriophage Mu d1 (Apr lac) generates vir-lac operon fusions in Shigella flexneri 2a. Infect. Immun. 1984, 45, 642.
109. 109 Maurelli, A.T. and Sansonetti, P.J. Identification of a chromosomal gene controlling temperature regulated expression of Shigella virulence. Proc. Natl Acad. Sci. USA 1988, 85, 2820.
110. 110 Maurelli, A.T. Regulation of virulence genes in Shigella. Molec. Biol. Med. 1989, 6, 425.
111. 111 Galan, J.E., Pace, J. and Hayman, M. Involvement of the epidermal growth factor receptor in the invasion of cultured mammalian cells by Salmonella typhimurium. Nature 1992, 357, 588.
112. 112 Norris, V., Chen, M., Goldberg, M., Voskull, J., McGurk, G. and Holland, I.B. Calcium in bacteria: a solution to which problem. Molec. Microbiol. 1991, 5, 775.
113. 113 Daskaleros, P.A. and Payne, S.M. Congo red binding phenotype is associated with hemin binding and increased infectivity of Shigella flexneri in the HeLa cell model. Infect. Immun. 1987, 55, 1393.
114. 114 Genco, C.A. and Desai, P.J. Iron acquisition in the pathogenic Neisseria. Trends Microbiol. 1996, 4, 179.
115. 115 Galan, J.E., Ginocchio, C. and Costeas, P. Molecular and functional characterization of the Salmonella invasion gene invA: homology of InvA to members of a new protein family. J. Bacteriol. 1992, 174, 4338.
116. 116 Miller, S., Pesci, E.C. and Pickett, C.L. A Campylobacter jejuni homolog of the Lcr/FlbF family of proteins is necessary for flagellar biogenesis. Infect. Immun. 1993, 61, 2930.
117. 117 Kaniga, K., Trollinger, D. and Galán, J.E. Identification of two targets of the type III protein secretion system encoded by the inv and spa loci Salmonella typhimurium that have homology to the Shigella IpaD and IpaA proteins. J. Bacteriol. 1995, 177, 7078.
118. 118 Ruiz-Palacios, G., Cervantes, L.E., Newburg, D.S., Lopez-Vidal, Y. and Calva, J.J. In vitro models for studying Campylobacter infections. In: Campylobacter jejuni : Current Status and Future Trends (Eds Nachamkin, I., Blaser, M.J. and Tompkins, L.S.). American Society of Microbiology, Washington, DC, 1992, pp. 176-183.
119. 119 Walker, R.I., Caldwell, M.B., Lee, E.C., Guerry, P., Trust, T.J. and Ruiz-Palacios, G.M. Pathophysiology of Campylobacter enteritis. Microbiol. Rev. 1986, 50, 81.
120. 120 Haberberger, R.L. and Walker, R.I. Prospects and problems for development of a vaccine against diarrhea caused by Campylobacter. Vaccine Res. 1994, 3, 15.
121. 121 Walker, R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994, 12, 387.
122. 122 Pace, J.L., Walker, R.I. and Frey, S.M. Preparation of enhanced antigenic Campylobacter jejuni and vaccine comprising same. US Patent 5,679,564 1997.
123. 123 Division of Microbiology and Infectious Diseases, NIAID, NIH. The Jordan Report: accelerated development of vaccines 1993, p. 86.
124. 124 Robbins, A. and Freeman, P. Obstacles to developing vaccines for the third world. Sci. Am. 1988, 259, 126.
125. 125 Jertborn, M., Åhrén, C., Holmgren, J. and Svennerholm, A.-M. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. Vaccine 1998, 16, 255.
126. 126 Evans, D.G., Evans, D.J. Jr., Opekun, A.R. and Graham, D.Y. Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiol. Immunol. 1988, 1, 117.
127. 127 Schmidt, M. Jr., Kelly, E.P., Tsang, L.Y. and Boedeker, E.G. Towards an oral Escherichia coli pilus vaccine for traveller's diarrhea: susceptibility of purified colonization factor antigen/ II to proteolytic digestion. Gastroenterology 1985, 88, 1575.
128. 128 Wenneras, C., Svennerholm, A.M. and Czerkinsky, C. Vaccine-specific T cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect. Immun. 1994, 62, 874.
129. 129 Svennerholm, A.M., Holmgren, J. and Sack, D. Development of oral vaccines against enterotoxigenic Escherichia coli diarrhea. Vaccine 1989, 7, 196.
130. 130 Donnelly, C.W. Listeria monocytogenes. In: Foodborne Diseases Handbook: Diseases Caused by Bacteria (Eds Hui, Y.H., Gorham, J.R., Murrell, K.D. and Cliver, D.O.), Vol. 1. Marcel-Dekker, New York, 1994, pp. 215-252.
131. 131 Szemeredi, G. and Padanyi, M. A ten year's experience with inactivated vaccine against listeriosis of sheep. Acta Microbiol. Hung. 1989, 36, 327.
132. 132 Robertsson, J.A., Lindberg, A.A., Hoiseth, S. and Stocker, B.A. Salmonella typhimurium infection in calves: protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines. Infect. Immun. 1983, 41, 742.
133. 133 Timms, L.M., Marshall, R.N. and Breslin, M.F. Laboratory assessment of protection given by an experimental Salmonella enteritidis PT4 inactivated, adjuvant vaccine. Vet. Rec. 1990, 127, 611.
134. 134 Timms, L.M., Marshall, R.N. and Breslin, M.F. Laboratory and field trial assessment of protection given by a Salmonella enteritidis PT4 inactivated, adjuvant vaccine. Br. Vet. J. 1994, 150, 93.
135. 135 Ivanoff, B., Levine, M.M. and Lambert, P.H. Vaccination against typhoid fever: present status. Bull. WHO 1994, 72, 957.
136. 136 Tacket, C.O. and Levine, M.M. Human typhoid vaccines-old and new. In: Molecular and Clinical Aspects of Bacterial Vaccine Development (Eds Ala'Aldeen, D.A.A. and Hormaeche, C.E.). Wiley, New York, 1995, pp. 150-165.
137. 137 Mallett, C.P., VanDeVerg, L., Collins, H.H. and Hale, T.L. Evaluation of Shigella vaccine safety and efficacy in an intransally challenged mouse model. Vaccine 1993, 11, 190.
138. 138 Sood, A., Sokhey, J., Sharma, S.B., Gairola, S., Singh, S. and Singh, H. Evaluation of a potency of inactivated cholera vaccine by mouse protection assay and antibody induction method. Ind. J. Med. Res. 1994, 100, 262.
139. 139 Clemens, J.D., Sack, D.A., Harris, J.R., Chakraborty, J., Khan, M.R., Stanton, B.F., Kay, B.A., Khan, M.U., Yunus, M. and Atkinson, W. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 333, 124.
140. 140 Clemens, J.D., Sack, D.A., Harris, J.R., Chakraborty, J., Khan, M.R., Stanton, B.F., Ali, M., Ahmed, F., Yunus, M. and Kay, B.A. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet 1988, 335, 1375.
141. 141 Clemens, J.D., Sack, D.A., Harris, J.R., Chakraborty, J., Neogy, P.K., Stanton, B., Huda, N., Khan, M.U., Kay, B.A. and Khan, M.R. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 1988, 158, 372.
142. 142 Holmgren, J., Svennerholm, A.M., Jertborn, M., Clemens, J., Sack, D.A., Salenstedt, R. and Wigzell, H. An oral B subunit: whole cell vaccine against cholera. Vaccine 1988, 10, 911.
143. 143 Jertborn, M., Svennerholm, A.M. and Holmgren, J. Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 1993, 11, 1007.
144. 144 Clemens, J.D., Stanton, B.F., Chakraborty, J., Sack, D.A., Khan, M.R., Huda, N., Ahmed, F., Harris, J.R., Yunus, M. and Khan, M.U. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J. Infect. Dis. 1987, 155, 79.
145. 145 Ciznar, I., Ahsan, C.R., Rahman, A., Shahabuddin, M., Bartkova, G., Clemens, J.D. and Sack, D.A. Crossed immunoelectrophoretic analysis of antigenic composition of B-subunit/whole-cell and whole-cell only killed oral cholera vaccines. Vaccine 1992, 10, 591.
146. 146 Ciznar, I., Hussain, N., Ahsan, C.R., Kay, B.A., Clemens, J.D. and Sack, D.A. Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. I. Cross-reacting antigens of members of family Vibrionaceae and the vaccines. Vaccine 1989, 7, 11.
147. 147 Lycke, N., Hellstrom, U. and Holmgren, J. Circulating cholera antitoxin memory cells in the blood one year after oral cholera vaccination in humans. Scand. J. Immunol. 1987, 26, 207.
148. 148 Trach, D.D., Clemens, J.D., Ke, N.T., Thuy, H.T., Son, N.D., Canh, D.G., Hang, P.V. and Rao, M.R. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997, 349, 231.
149. 149 Murray, C.J.L. and Lopez, A.D. Global Health Statistics. Global Burden of Disease and Injury Series, Vol. II. The Harvard School of Public Health, 1996, p. 906.
150. 150 Noah, N.D. Attack rates of notified whooping cough in immunised and unimmunized children. Br. Med. J. 1976, 1, 128.
151. 151 Miller, D.L., Alderslade, R. and Ross, E.M. Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol. Rev. 1982, 4, 1.
152. 152 Mortimer, E.A. Jr Pertussis vaccine. In: Vaccines (Eds Plotkin, S.A. and Mortimer, E.A. Jr), 2nd edn. W.B. Saunders, Philadelphia, PA, 1995, pp. 91-135.
153. 153 Halperin, S.A., Eastwood, B.J., Barreto, L., Friesen, B., Medd, L., Meekinson, W. and Guasparini, R. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diptheria and tetanus toxoids in the first 19 months of life. Vaccine 1996, 14, 767.
154. 154 Alonso, J.M., Rocancourt, M., Le Nin, S. and Brezin, C. Experimental models for testing Bordetella pertussis virulence and immunogenicity. Ann. Scalvo Collana Monogr. 1986, 3, 319.
155. 155 Sato, H. and Sato, Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect. Immun. 1984, 46, 415.
156. 156 Thomas, M.G., Redhead, K. and Lambert, H.P. Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination. J. Infect. Dis. 1989, 159, 211.
157. 157 Willems, J.L, Kamerbeck, J., Geuijen, C.A.W., Top, J., Gielen, H., Gaastra, W. and Mooi, F.R. The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model. Vaccine 1998, 16, 410.
158. 158 Tandon, M.K. and Gebski, V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Aust. N. Z. J. Med. 1991, 21, 427.
159. 159 Mouahid, M., Bouzoubaa, K. and Zouagui, Z. Preparation and use of an autogenous bacterin against infectious coryza in chickens. Vet. Res. Commun. 1991, 15, 413.
160. 160 Smart, I.E., Dougall, A.J. and Girdwood, R.W. New 23-valent pneumococcal vaccine in relation to pneumococcal serotypes in systemic and nonsystemic disease. J. Infect. 1987, 14, 209.
161. 161 American Academy of Pediatrics. Pneumococcal infections. In: 7994 Red Book: Report of the Committee on Infectious Diseases (Ed. Peter, G.), 23rd edn. American Academy of Pediatrics, Elk Grove Village, IL, 1994.
162. 162 Arya, S.C., Ashraf, S.J. and Pathak, V.P. Glutaraldehyde in whole-cell Bordetella pertussis vaccine. Vaccine 1989, 7, 486.
163. 163 Gupta, R.K., Sharma, S.B., Ahuja, S. and Saxena, S.N. Glutaraldehyde inactivated pertussis vaccine: a less histamine sensitizing vaccine. J. Biol. Stand. 1987, 15, 159.
164. 164 Gupta, R.K., Saxena, S.N., Sharma, S.B. and Ahuja, S. Studies on the optimal conditions for inactivation of Bordetella pertussis organisms with glutar-aldehyde for preparation of a safe and potent pertussis vaccine. Vaccine 1988, 6, 491.
165. 165 Iida, T. and Horiuchi, Y. The detoxification of Bordetella pertussis with glutaraldehyde. J. Biol. Stand. 1987, 15, 17.
166. 166 Saran, G. Acetone-treated pertussis vaccine-a potent and safer new pertussis vaccine. J. Biol. Stand. 1985, 13, 315.
167. 167 Cryz, S.J. Jr., Furer, E. and Germanier, R. Effect of chemical and heat inaclivation on the antigenicity and immunogenicity of Vibrio cholerae. Infect. Immun. 1982, 38, 21.
168. 168 Cryz, S.J. Jr., Furer, E. and Germanier, R. Immunogenicity and protective capacity of inactivated Vibrio cholerae whole cell vaccines. Dev. Biol. Stand. 1983, 53, 67.
169. 169 Cárdenas, L., Dasgupta, U. and Clements, J.D. Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine 1994, 12, 833.